Display options
Cite
Sioud M, Westby P, Olsen JK, et al. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Mol Ther Methods Clin Dev. 2015;2:15043doi: 10.1038/mtm.2015.43.
Sioud, M., Westby, P., Olsen, J. K., & Mobergslien, A. (2015). Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Molecular therapy. Methods & clinical development, 215043. https://doi.org/10.1038/mtm.2015.43
Sioud, Mouldy, et al. "Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells." Molecular therapy. Methods & clinical development vol. 2 (2015): 15043. doi: https://doi.org/10.1038/mtm.2015.43
Sioud M, Westby P, Olsen JK, Mobergslien A. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Mol Ther Methods Clin Dev. 2015 Nov 04;2:15043. doi: 10.1038/mtm.2015.43. eCollection 2015. PMID: 26605373; PMCID: PMC4632835.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Methods Clin Dev. 2015 Nov 04;2:15043. doi: 10.1038/mtm.2015.43. eCollection 2015.

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells.

Molecular therapy. Methods & clinical development

Mouldy Sioud, Phuong Westby, Julie Kristine E Olsen, Anne Mobergslien

Affiliations

  1. Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital , Montebello, Oslo, Norway.

PMID: 26605373 PMCID: PMC4632835 DOI: 10.1038/mtm.2015.43

Abstract

Antibody-dependent cellular cytotoxicity (ADCC), a key effector function for the clinical effectiveness of monoclonal antibodies, is triggered by the engagement of the antibody Fc domain with the Fcγ receptors expressed by innate immune cells such as natural killer (NK) cells and macrophages. Here, we fused cancer cell-binding peptides to the Fc domain of human IgG1 to engineer novel peptide-Fc fusion proteins with ADCC activity. The designed fusion proteins were expressed in human embryonic kidney 293T cells, followed by purification and characterization by western blots. One of the engineered variants (WN-Fc), bound with high affinity to a wide range of solid tumor cell lines (e.g., colon, lung, prostate, skin, ovarian, and mammary tumors). Treatment of cancer cells with the engineered peptide-Fc fusions in the presence of effector NK cells potentially enhanced cytotoxicity, degranulation, and interferon-γ production by NK cells when compared to cells treated with the Fc control. The presence of competing peptides inhibited NK cell activation. Furthermore, a bispecific peptide-Fc fusion protein activated NK cells against HER-1- and/or HER-2-expressing cancer cells. Collectively, the engineered peptide-Fc fusions constitute a new promising strategy to recruit and activate NK cells against tumor cells, a primary goal of cancer immunotherapy.

References

  1. Cancer Res. 2004 Mar 15;64(6):2127-33 - PubMed
  2. Oncotarget. 2013 Oct;4(10):1819-28 - PubMed
  3. Nanomedicine (Lond). 2010 Jun;5(4):563-74 - PubMed
  4. Cancer Res. 2007 Apr 1;67(7):3337-44 - PubMed
  5. J Control Release. 2014 May 28;182:13-21 - PubMed
  6. Biomacromolecules. 2014 Aug 11;15(8):2971-81 - PubMed
  7. Curr Opin Biotechnol. 2009 Dec;20(6):692-9 - PubMed
  8. Drug Resist Updat. 2003 Dec;6(6):363-71 - PubMed
  9. J Pharm Sci. 2014 Jan;103(1):53-64 - PubMed
  10. Trends Biotechnol. 2008 Apr;26(4):210-7 - PubMed
  11. Cancer Res. 2006 Oct 15;66(20):10073-82 - PubMed
  12. MAbs. 2012 Sep-Oct;4(5):586-91 - PubMed
  13. Nat Rev Immunol. 2010 May;10(5):345-52 - PubMed
  14. Breast Cancer Res. 2011 Apr 15;13(2):R44 - PubMed
  15. J Clin Oncol. 2012 Feb 1;30(4):362-71 - PubMed
  16. J Clin Oncol. 2009 Jul 20;27(21):3557-65 - PubMed
  17. J Control Release. 2010 Apr 2;143(1):136-42 - PubMed
  18. FASEB J. 2013 Aug;27(8):3272-83 - PubMed
  19. Cancer Sci. 2011 Jan;102(1):1-8 - PubMed
  20. Expert Rev Anticancer Ther. 2012 Dec;12(12):1591-6 - PubMed
  21. Clin Cancer Res. 2005 Mar 15;11(6):2327-36 - PubMed
  22. Chem Rev. 2005 Nov;105(11):4056-72 - PubMed
  23. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1527-31 - PubMed
  24. Eur J Cancer. 2014 Aug;50(12):2010-9 - PubMed
  25. Scand J Immunol. 2010 Apr;71(4):267-74 - PubMed
  26. BMC Biotechnol. 2015 Jun 27;15:61 - PubMed
  27. Bioconjug Chem. 2008 Sep;19(9):1813-21 - PubMed
  28. FASEB J. 2011 Jun;25(6):1865-73 - PubMed
  29. Chem Rev. 1997 Apr 1;97(2):391-410 - PubMed
  30. Science. 2011 Jan 7;331(6013):44-9 - PubMed
  31. Nat Med. 2014 Jun;20(6):676-81 - PubMed
  32. Nat Rev Cancer. 2005 May;5(5):341-54 - PubMed
  33. J Mol Biol. 2001 Nov 9;313(5):965-76 - PubMed
  34. Nat Immunol. 2008 May;9(5):503-10 - PubMed
  35. Br J Haematol. 2010 Jul;150(1):9-20 - PubMed
  36. Lancet. 2004 Feb 28;363(9410):675-81 - PubMed
  37. PLoS One. 2014 Oct 22;9(10):e110632 - PubMed
  38. Blood. 2010 Jun 3;115(22):4393-402 - PubMed
  39. Nature. 1996 Mar 28;380(6572):364-6 - PubMed
  40. Mol Cancer Ther. 2008 Mar;7(3):579-89 - PubMed
  41. J Immunol. 2014 Mar 1;192(5):2252-60 - PubMed
  42. J Immunol Methods. 1989 Dec 20;125(1-2):167-76 - PubMed
  43. Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 - PubMed
  44. Pharmacol Ther. 2008 Feb;117(2):244-79 - PubMed
  45. Cancer Lett. 2003 Dec 30;202(2):219-30 - PubMed
  46. FASEB J. 2003 Feb;17(2):256-8 - PubMed
  47. Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 - PubMed
  48. Exp Hematol. 2006 Apr;34(4):443-52 - PubMed
  49. Clin Pharmacokinet. 2010 Aug;49(8):493-507 - PubMed
  50. FASEB J. 2005 Dec;19(14 ):1978-85 - PubMed
  51. Cancer Sci. 2009 Sep;100(9):1566-72 - PubMed
  52. Front Immunol. 2013 Mar 27;4:76 - PubMed
  53. Nat Rev Immunol. 2008 Jan;8(1):34-47 - PubMed

Publication Types